Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
andecaliximab + gemcitabine + nab-paclitaxel
- Development stage
- Phase 1
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
A combination regimen consisting of **andecaliximab**, a monoclonal antibody targeting matrix metalloproteinase 9 (MMP9); **gemcitabine**, a nucleoside analogue antimetabolite; and **nab-paclitaxel** (nanoparticle albumin-bound paclitaxel, marketed as Abraxane), an antimicrotubule agent. Andecaliximab inhibits MMP9, an extracellular enzyme involved in the degradation of the extracellular matrix, tumor invasion, and metastasis. Gemcitabine is incorporated into DNA and inhibits DNA synthesis, leading to apoptosis. Nab-paclitaxel stabilizes microtubules and inhibits cell division. This combination is being studied for synergistic effects in solid tumors (notably pancreatic cancer) and is administered intravenously[1][2][3][4][5].
- Other names
- nanoparticle albumin-bound paclitaxel + gemcitabine + andecaliximab
02
Targets
DNAMMP9 (Matrix metalloproteinase-9)MicrotubuleTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on andecaliximab + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on andecaliximab + gemcitabine + nab-paclitaxel.